Clinical Trial Update: A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating weekly alternating sequential administration of BIBF 1120 and BIBW 2992 in advanced colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• BIBF 1120 (nintedanib)
• BIBW 2992 (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED